Tigermed(300347) 智通财经·2024-03-28 09:12Core Insights - The company reported a revenue of 7.384 billion yuan for 2023, representing a year-on-year growth of 4.2% [1] - Gross profit was approximately 2.821 billion yuan, with a year-on-year increase of 1.3% [1] - Net profit attributable to shareholders was 2.0265 billion yuan, up 0.5% year-on-year, while adjusted net profit reached 1.786 billion yuan, reflecting a 7.2% increase [1] - Earnings per share stood at 2.34 yuan, with a final dividend of 5.68 yuan for every 10 shares [1] Revenue Breakdown - Revenue from China amounted to 4.2345 billion yuan, marking a significant year-on-year growth of 17.6%, driven by the company's leading position in the Chinese clinical services market and increased revenue from clinical trials for drugs and medical devices [1] - The company experienced rapid growth in on-site management and patient recruitment services in 2023 [1] - Revenue from data management, statistical analysis, scientific affairs, medical imaging, real-world research, and pharmacovigilance services also saw steady growth in 2023 [1] - Conversely, overseas revenue was 3.1495 billion yuan, showing a decline of 9.6%, primarily due to reduced income from multi-regional clinical trials related to COVID-19 vaccines during the reporting period [1] Business Development - The company recorded a net new order amount of 7.852 billion yuan in 2023, which represents a year-on-year decline of 18.8% [1] - The decrease in new orders was attributed to some clients canceling previous orders in the fourth quarter of 2023 or experiencing negative changes during project execution [1] - Additionally, the handling fees for new orders saw a significant year-on-year decline in 2023 [1]